WAP
REGN icon

Wealthcare Advisory Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Wealthcare Advisory Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-287
Closed -$204K – 943
2024
Q4 		$204K Sell
287
-11
-4% -$9.23K 0.01% 857
2024
Q3 		$313K Buy
298
+1
+0.3% +$1.11K 0.01% 706
2024
Q2 		$312K Buy
297
+3
+1% +$2.91K 0.01% 661
2024
Q1 		$283K Buy
294
+37
+14% +$35.2K 0.01% 689
2023
Q4 		$226K Buy
+257
New +$212K 0.01% 685
2021
Q2 		– Sell
-91
Closed -$43K – 1562
2021
Q1 		$43K Buy
+91
New +$44.3K ﹤0.01% 928
2019
Q3 		– Sell
-40
Closed -$13K – 1402
2019
Q2 		$13K Sell
40
-15
-27% -$4.99K ﹤0.01% 848
2019
Q1 		$23K Hold
55
– – ﹤0.01% 625
2018
Q4 		$21K Sell
55
-28
-34% -$10.2K ﹤0.01% 617
2018
Q3 		$34K Buy
83
+15
+22% +$5.71K 0.01% 553
2018
Q2 		$23K Hold
68
– – ﹤0.01% 641
2018
Q1 		$23K Sell
68
-1
-1% -$348 0.01% 556
2017
Q4 		$26K Buy
69
+44
+176% +$17.8K 0.01% 486
2017
Q3 		$11K Buy
+25
New +$11.9K ﹤0.01% 528

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wealthcare Advisory Partners's REGN Position: Q1 2025 in Review

Wealthcare Advisory Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 287 shares — an estimated $204K sold.

Wealthcare Advisory Partners first reported a position in REGN in Q3 2017 and held it in 14 quarters. The position peaked at $313K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Wealthcare Advisory Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 287 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $204K.
  • Wealthcare Advisory Partners first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 14 quarters.
  • Wealthcare Advisory Partners's Regeneron Pharmaceuticals position peaked at $313K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Wealthcare Advisory Partners's 13F filing for Q1 2025, filed 15 Apr 2025.